Published in J Neurochem on November 10, 2008
The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res (2009) 2.61
Dynorphin, stress, and depression. Brain Res (2009) 2.45
Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology (Berl) (2010) 1.90
Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell (2009) 1.83
Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev (2011) 1.66
Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology (2011) 1.50
Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev (2011) 1.26
Development of functionally selective, small molecule agonists at kappa opioid receptors. J Biol Chem (2013) 1.17
Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons. J Biol Chem (2013) 1.08
The role of kappa-opioid receptor activation in mediating antinociception and addiction. Acta Pharmacol Sin (2010) 0.95
Does the kappa opioid receptor system contribute to pain aversion? Front Pharmacol (2014) 0.92
Inhibition of EGF-induced ERK/MAP kinase-mediated astrocyte proliferation by mu opioids: integration of G protein and beta-arrestin 2-dependent pathways. J Neurochem (2009) 0.90
Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A. Br J Pharmacol (2014) 0.89
Ligand directed signaling differences between rodent and human κ-opioid receptors. J Biol Chem (2012) 0.88
Morphine modulation of thrombospondin levels in astrocytes and its implications for neurite outgrowth and synapse formation. J Biol Chem (2010) 0.88
Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment. Prog Neuropsychopharmacol Biol Psychiatry (2015) 0.87
Mu and kappa opioids modulate mouse embryonic stem cell-derived neural progenitor differentiation via MAP kinases. J Neurochem (2009) 0.86
Identifying ligand-specific signalling within biased responses: focus on δ opioid receptor ligands. Br J Pharmacol (2014) 0.83
Serine 363 is required for nociceptin/orphanin FQ opioid receptor (NOPR) desensitization, internalization, and arrestin signaling. J Biol Chem (2012) 0.81
Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias. ACS Chem Neurosci (2015) 0.81
Molecular approaches for manipulating astrocytic signaling in vivo. Front Cell Neurosci (2015) 0.81
Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse. Adv Pharmacol (2014) 0.81
Functional Selectivity of Kappa Opioid Receptor Agonists in Peripheral Sensory Neurons. J Pharmacol Exp Ther (2015) 0.77
Acute and chronic mu opioids differentially regulate thrombospondins 1 and 2 isoforms in astrocytes. ACS Chem Neurosci (2013) 0.75
Enhancing Remyelination through a Novel Opioid-Receptor Pathway. J Neurosci (2016) 0.75
Nor-Binaltorphimine Blocks the Adverse Effects of Morphine after Spinal Cord Injury. J Neurotrauma (2016) 0.75
Mechanism Governing Human Kappa-Opioid Receptor Expression under Desferrioxamine-Induced Hypoxic Mimic Condition in Neuronal NMB Cells. Int J Mol Sci (2017) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Transduction of receptor signals by beta-arrestins. Science (2005) 9.87
Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell (2005) 7.41
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther (2006) 7.03
beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem (2005) 4.91
Glia-derived D-serine controls NMDA receptor activity and synaptic memory. Cell (2006) 4.53
Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A (2002) 4.34
Astrocytes promote myelination in response to electrical impulses. Neuron (2006) 4.23
Origin and progeny of reactive gliosis: A source of multipotent cells in the injured brain. Proc Natl Acad Sci U S A (2008) 3.44
A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem (1997) 3.12
New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol Cell (2006) 3.11
Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem (2004) 3.07
Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem (2006) 3.00
Astrocyte dysfunction in neurological disorders: a molecular perspective. Nat Rev Neurosci (2006) 2.76
beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. J Biol Chem (2002) 2.42
Contribution of astrocytes to hippocampal long-term potentiation through release of D-serine. Proc Natl Acad Sci U S A (2003) 2.35
Two types of astrocytes in cultures of developing rat white matter: differences in morphology, surface gangliosides, and growth characteristics. J Neurosci (1983) 2.18
An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization. Mol Pharmacol (2006) 2.06
Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J Biol Chem (2006) 1.97
Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. J Biol Chem (2007) 1.91
Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol (2005) 1.86
Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues. Bioorg Med Chem Lett (2005) 1.79
beta-Arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. J Biol Chem (2004) 1.75
Direct astrocytic contacts regulate local maturation of dendritic spines. J Neurosci (2007) 1.70
Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol Pharmacol (2004) 1.67
HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain (1998) 1.65
Specification of astrocytes by bHLH protein SCL in a restricted region of the neural tube. Nature (2005) 1.62
Genome-wide transcriptional analysis of the human cell cycle identifies genes differentially regulated in normal and cancer cells. Proc Natl Acad Sci U S A (2008) 1.53
Mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes. J Biol Chem (2005) 1.46
Egr-1 activates basic fibroblast growth factor transcription. Mechanistic implications for astrocyte proliferation. J Biol Chem (1996) 1.39
Dual effect of beta-adrenergic receptors on mitogen-activated protein kinase. Evidence for a beta gamma-dependent activation and a G alpha s-cAMP-mediated inhibition. J Biol Chem (1995) 1.33
Sciatic nerve ligation-induced proliferation of spinal cord astrocytes is mediated by kappa opioid activation of p38 mitogen-activated protein kinase. J Neurosci (2007) 1.31
mu-Opioid receptor-mediated ERK activation involves calmodulin-dependent epidermal growth factor receptor transactivation. J Biol Chem (2001) 1.27
Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. Neuroimage (2008) 1.23
Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves Gbetagamma subunits. J Neurochem (1998) 1.21
Pathobiology of dynorphins in trauma and disease. Front Biosci (2005) 1.17
Ephrins as negative regulators of adult neurogenesis in diverse regions of the central nervous system. Proc Natl Acad Sci U S A (2008) 1.16
Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade. J Neurochem (2000) 1.12
Expression of astrocytic markers aquaporin 4 and connexin 43 is altered in brains of subjects with autism. Synapse (2008) 1.11
Morphine modulates chemokine gene regulation in normal human astrocytes. Clin Immunol (2005) 1.09
Directed establishment of rat brain cell lines with the phenotypic characteristics of type 1 astrocytes. Proc Natl Acad Sci U S A (1992) 1.09
Differential helical orientations among related G protein-coupled receptors provide a novel mechanism for selectivity. Studies with salvinorin A and the kappa-opioid receptor. J Biol Chem (2006) 1.04
Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem (2008) 1.03
Basic fibroblast growth factor-induced proliferation of primary astrocytes. evidence for the involvement of sphingomyelin biosynthesis. J Biol Chem (2001) 1.03
Mu opioid transactivation and down-regulation of the epidermal growth factor receptor in astrocytes: implications for mitogen-activated protein kinase signaling. Mol Pharmacol (2003) 1.02
kappa-Opioid agonist modulation of [3H]thymidine incorporation into DNA: evidence for the involvement of pertussis toxin-sensitive G protein-coupled phosphoinositide turnover. J Neurochem (1993) 1.01
Roles of Src and epidermal growth factor receptor transactivation in transient and sustained ERK1/2 responses to gonadotropin-releasing hormone receptor activation. J Biol Chem (2003) 1.00
Opioids inhibit endothelin-mediated DNA synthesis, phosphoinositide turnover, and Ca2+ mobilization in rat C6 glioma cells. J Neurosci (1994) 0.98
Morphine alters astrocyte growth in primary cultures of mouse glial cells: evidence for a direct effect of opiates on neural maturation. Brain Res Dev Brain Res (1991) 0.97
Diversity of the endogenous opioid system in development. Novel signal transduction translates multiple extracellular signals into neural cell growth and differentiation. Perspect Dev Neurobiol (1998) 0.96
Salvinorin A: a novel and highly selective kappa-opioid receptor agonist. Life Sci (2004) 0.95
Phospholipase D activation by endogenous 5-hydroxytryptamine 2C receptors is mediated by Galpha13 and pertussis toxin-insensitive Gbetagamma subunits. Mol Pharmacol (2002) 0.90
Characterization of opioid-dependent glial development in dissociated and organotypic cultures of mouse central nervous system: critical periods and target specificity. Brain Res Dev Brain Res (1991) 0.90
Dual growth arrest pathways in astrocytes and astrocytic tumors in response to Raf-1 activation. J Biol Chem (2001) 0.89
Ectopia of meningeal fibroblasts and reactive gliosis in the cerebral cortex of the mouse model of muscle-eye-brain disease. J Comp Neurol (2007) 0.88
Coupling of ETB endothelin receptor to mitogen-activated protein kinase stimulation and DNA synthesis in primary cultures of rat astrocytes. J Neurochem (1996) 0.88
Cyclic AMP inhibits activation of mitogen-activated protein kinase and cell proliferation in response to growth factors in cultured rat cortical astrocytes. J Neurochem (1996) 0.88
Astroglial differentiation is required for support of neurite outgrowth. J Neurosci (1994) 0.87
Biomodulatory role of ceramide in basic fibroblast growth factor-induced proliferation of cerebellar astrocytes in primary culture. Glia (2000) 0.84
Apolipoprotein E deposition and astrogliosis are associated with maturation of beta-amyloid plaques in betaAPPswe transgenic mouse: Implications for the pathogenesis of Alzheimer's disease. Brain Res (2001) 0.83
Extracellular ATP stimulates an inhibitory pathway towards growth factor-induced cRaf-1 and MEKK activation in astrocyte cultures. J Neurochem (2001) 0.83
Dynorphins modulate DNA synthesis in fetal brain cell aggregates. J Neurochem (1995) 0.82
Evidence for transduction of mu but not kappa opioid modulation of extracellular signal-regulated kinase activity by G(z) and G(12) proteins. Cell Signal (2000) 0.81
Astrocytes put down the broom and pick up the baton. Cell (2006) 0.77
Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci (2004) 4.44
Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology (2013) 3.35
Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci (2006) 2.84
Gastric bypass and banding equally improve insulin sensitivity and β cell function. J Clin Invest (2012) 2.19
Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron (2003) 2.03
Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron (2011) 1.83
Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther (2005) 1.79
Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer. Mol Pharmacol (2005) 1.73
Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci U S A (2010) 1.63
Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev (2011) 1.61
ATP hydrolysis-dependent disassembly of the 26S proteasome is part of the catalytic cycle. Cell (2005) 1.55
Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci U S A (2008) 1.51
Mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes. J Biol Chem (2005) 1.46
Interleukin-1 stimulates beta-cell necrosis and release of the immunological adjuvant HMGB1. PLoS Med (2005) 1.45
Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain. Nat Chem (2011) 1.44
Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology (2006) 1.39
The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology (2010) 1.30
Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J Biol Chem (2012) 1.28
Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci U S A (2003) 1.27
A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse (2007) 1.24
Role of delta-opioid receptor function in neurogenesis and neuroprotection. J Neurochem (2006) 1.23
Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo. J Neurosci (2010) 1.21
Posttranslational, translational, and transcriptional responses to nitric oxide stress in Cryptococcus neoformans: implications for virulence. Eukaryot Cell (2006) 1.21
Direct evidence for the involvement of brain-derived neurotrophic factor in the development of a neuropathic pain-like state in mice. J Neurochem (2005) 1.21
Direct evidence for spinal cord microglia in the development of a neuropathic pain-like state in mice. J Neurochem (2006) 1.20
Identification of Drosophila neuropeptide receptors by G protein-coupled receptors-beta-arrestin2 interactions. J Biol Chem (2003) 1.20
Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation. Mol Pharmacol (2011) 1.20
Development of functionally selective, small molecule agonists at kappa opioid receptors. J Biol Chem (2013) 1.17
Mu opioid receptor regulation and opiate responsiveness. AAPS J (2005) 1.16
Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther (2008) 1.15
Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation. J Biol Chem (2011) 1.13
Stimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colon. Am J Physiol Gastrointest Liver Physiol (2009) 1.12
Implication of activated astrocytes in the development of drug dependence: differences between methamphetamine and morphine. Ann N Y Acad Sci (2008) 1.10
Mu- and kappa-opioids induce the differentiation of embryonic stem cells to neural progenitors. J Biol Chem (2006) 1.08
Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons. J Biol Chem (2013) 1.08
Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse. J Pharmacol Exp Ther (2010) 1.08
Diversity of G protein-coupled receptor signaling pathways to ERK/MAP kinase. Neurosignals (2002) 1.07
PPARgamma ligands induce ER stress in pancreatic beta-cells: ER stress activation results in attenuation of cytokine signaling. Am J Physiol Endocrinol Metab (2004) 1.04
Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem (2008) 1.03
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues. Bioorg Med Chem Lett (2011) 1.03
Mu opioid transactivation and down-regulation of the epidermal growth factor receptor in astrocytes: implications for mitogen-activated protein kinase signaling. Mol Pharmacol (2003) 1.02
Apparent loss-of-function mutant GPCRs revealed as constitutively desensitized receptors. Biochemistry (2002) 1.02
Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend (2011) 1.00
Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine. Dig Dis Sci (2010) 1.00
Repair of nitric oxide-damaged DNA in beta-cells requires JNK-dependent GADD45alpha expression. J Biol Chem (2009) 0.98
β-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner. Biol Psychiatry (2012) 0.97
Characterization of conditioned place preference to cocaine in congenic dopamine transporter knockout female mice. Psychopharmacology (Berl) (2005) 0.96
Drosophila CG8422 encodes a functional diuretic hormone receptor. J Exp Biol (2004) 0.96
SCF E3-mediated autoubiquitination negatively regulates activity of Cdc34 E2 but plays a nonessential role in the catalytic cycle in vitro and in vivo. Mol Cell Biol (2007) 0.96
Chronic pain-induced emotional dysfunction is associated with astrogliosis due to cortical delta-opioid receptor dysfunction. J Neurochem (2006) 0.96
Nitric oxides mediates a shift from early necrosis to late apoptosis in cytokine-treated β-cells that is associated with irreversible DNA damage. Am J Physiol Endocrinol Metab (2009) 0.94
Morphine-induced physiological and behavioral responses in mice lacking G protein-coupled receptor kinase 6. Drug Alcohol Depend (2009) 0.94
Mice with an adipocyte-specific lipin 1 separation-of-function allele reveal unexpected roles for phosphatidic acid in metabolic regulation. Proc Natl Acad Sci U S A (2012) 0.93
Alpha-dystrobrevin-1 recruits alpha-catulin to the alpha1D-adrenergic receptor/dystrophin-associated protein complex signalosome. Proc Natl Acad Sci U S A (2010) 0.93
GIRK channel modulation by assembly with allosterically regulated RGS proteins. Proc Natl Acad Sci U S A (2012) 0.91
Implication of protein kinase C in the orexin-induced elevation of extracellular dopamine levels and its rewarding effect. Eur J Neurosci (2007) 0.90
Inhibition of EGF-induced ERK/MAP kinase-mediated astrocyte proliferation by mu opioids: integration of G protein and beta-arrestin 2-dependent pathways. J Neurochem (2009) 0.90
Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. ACS Chem Neurosci (2012) 0.89
Ligand directed signaling differences between rodent and human κ-opioid receptors. J Biol Chem (2012) 0.88
Morphine modulation of thrombospondin levels in astrocytes and its implications for neurite outgrowth and synapse formation. J Biol Chem (2010) 0.88
The fibroblast growth factor receptor is at the site of convergence between mu-opioid receptor and growth factor signaling pathways in rat C6 glioma cells. J Pharmacol Exp Ther (2002) 0.88
Sexually dimorphic effect of aging on skeletal muscle protein synthesis. Biol Sex Differ (2012) 0.87
β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia. Handb Exp Pharmacol (2014) 0.87
Long-lasting change in brain dynamics induced by methamphetamine: enhancement of protein kinase C-dependent astrocytic response and behavioral sensitization. J Neurochem (2005) 0.86
Mu and kappa opioids modulate mouse embryonic stem cell-derived neural progenitor differentiation via MAP kinases. J Neurochem (2009) 0.86
Post-activation-mediated changes in opioid receptors detected by N-terminal antibodies. J Biol Chem (2008) 0.86
Differential effects of gestational buprenorphine, naloxone, and methadone on mesolimbic mu opioid and ORL1 receptor G protein coupling. Brain Res Dev Brain Res (2004) 0.86
A putative sigma1 receptor antagonist NE-100 attenuates the discriminative stimulus effects of ketamine in rats. Addict Biol (2001) 0.85
Behavioral sensitization to the discriminative stimulus effects of methamphetamine in rats. Eur J Pharmacol (2004) 0.84
Role of neuronal NR2B subunit-containing NMDA receptor-mediated Ca2+ influx and astrocytic activation in cultured mouse cortical neurons and astrocytes. Synapse (2006) 0.82
Lack of development of behavioral sensitization to methylphenidate in mice: correlation with reversible astrocytic activation. Eur J Pharmacol (2007) 0.80
[Role of astrocytes in rewarding effects of drugs of abuse]. Nihon Shinkei Seishin Yakurigaku Zasshi (2006) 0.79
Pharmacological characterization of a selective agonist for bombesin receptor subtype-3. Biochem Biophys Res Commun (2009) 0.79
Selective mtDNA mutation accumulation results in beta-cell apoptosis and diabetes development. Am J Physiol Endocrinol Metab (2009) 0.79
Serum response factor controls transcriptional network regulating epidermal function and hair follicle morphogenesis. J Invest Dermatol (2012) 0.78
Involvement of spinal metabotropic glutamate receptor 5 in the development of tolerance to morphine-induced antinociception. J Neurochem (2005) 0.77
Role of spinal voltage-dependent calcium channel alpha 2 delta-1 subunit in the expression of a neuropathic pain-like state in mice. Life Sci (2007) 0.77
Enhancement of dopamine-induced signaling responses in the forebrain of mice lacking dopamine D3 receptor. Neurosci Lett (2004) 0.77
Increased opioid receptor binding and G protein coupling in the accumbens and ventral tegmental area of postnatal day 2 rats. Neurosci Lett (2005) 0.76
Role of dopamine D2 and D3 receptors in mediating the U-50,488H discriminative cue: comparison with methamphetamine and cocaine. Addict Biol (2010) 0.75
Acute and chronic mu opioids differentially regulate thrombospondins 1 and 2 isoforms in astrocytes. ACS Chem Neurosci (2013) 0.75
Chemical warfare agent and biological toxin-induced pulmonary toxicity: could stem cells provide potential therapies? Inhal Toxicol (2013) 0.75
[The functional change in the 5-HT1A receptor induced by stress and the role of the 5-HT1A receptor in neuroprotection]. Nihon Shinkei Seishin Yakurigaku Zasshi (2005) 0.75
Correction to "Structure-Activity Relationship Studies of Functionally Selective Kappa Opioid Receptor Agonists that Modulate ERK 1/2 Phosphorylation While Preserving G Protein Over βArrestin2 Signaling Bias". ACS Chem Neurosci (2017) 0.75
[The implication of protein kinase C in the cell-cell interaction during the development of dependence on morphine]. Nihon Yakurigaku Zasshi (2006) 0.75
[Behavioral analysis of chronic exposure to diphenylarsinic and associated influence on central nervous systems]. Nihon Shinkei Seishin Yakurigaku Zasshi (2007) 0.75
[Implication of glial function in the development of drug dependence associated with synaptic plasticity]. Nihon Yakurigaku Zasshi (2005) 0.75